CD8A and neoplasm: Analysis of tumor-associated immune cells demonstrated that the combination of Lumacaftor and anti-PD-1 treatment significantly increased the percentage of CD8+ T cells but had no significant effect on CD4+ T cells (Fig. 8d, e).